ResMed Inc. (NYSE:RMD) finished Friday with an addition of $4.46 to close at $267.50, an upside of 1.70 percent. An average of 648,720 shares of common stock have been traded in the last five days. There was a gain of $12.01 in the past week, and it reached a new high 44 times over the past 12 months. The last 20 days have seen an average of 630,100 shares traded, while the 50-day average volume stands at 517,844.
RMD stock has decreased by -5.39% in the last month. The company shares reached their 1-month lowest point of $251.04 on 10/13/21. With the stock rallying to its 52-week high on 09/09/21, shares of the company touched a low of $177.70 and a high of $301.34 in 52 weeks. It has reached a new high 43 times so far this year and achieved 25.85% or $54.94 in price. In spite of this, the price is down -11.23% from the 52-week high.
3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
8 days have passed since ResMed Inc. (RMD) last reported insider trading activity. Douglas Robert Andrew, who is President and COO ResMed Inc., most recently acquired $8,000 shares at $255.77 per share on Oct 15. In this transaction, the insider spent $2,046,160. Chief Financial Officer, Sandercock Brett, disposed of 5,000 shares at a price of $253.37 on Oct 11. The insider now owns more than $1,266,850 worth of shares. Prior to that, Chief Administrative Officer PENDARVIS DAVID went on to Sale 1,487 shares at $260.79 each on Oct 04. An amount of $387,795 was transacted.
ResMed Inc. (RMD) has a trailing price-to-earnings (P/E) ratio of 82.61, which compares with the 26.30 for the broader industry and 33.43 for the sector. In the last five years, ResMed Inc.’s PE ratio has ranged between 91.78 and 23.40. The stock’s beta is 0.31. Other valuation ratios to consider include the trailing price-to-sales (P/S) ratio at 12.15, the price-to-book (PB) ratio at 13.50, and the price-to-cash flow ratio at 95.35.
ResMed Inc. pays a $1.68 dividend per share annually. It offers a dividend yield of 0.63%. The company has a payout ratio of 47.70%. The company’s most recent quarterly dividend payment took place on Sep. 23, and it was $0.42 a share, representing a up of 7.69% from $0.39 last year. Its dividend has been increased for the last 1 year with the latest increase dividend $0.03 reported on Thursday August 5 2021.Dividends have grown by 14.71% each year over the last three years.
The quick ratio of ResMed Inc. for the three months ended June 29 was 1.20, and the current ratio was 1.70, indicating that the company is able to meet its debt obligations. Further, the company has a long term debt to equity ratio of 0.22 and a total debt to equity ratio of 0.23 for the quarter ending June 29. ResMed Inc.’s EBITDA margin for the year ending June 29 is 34.53%, while its operating margin for the same period stands at 28.30%. Its gross profit as reported stood at $1.84 billion compared to revenue of $3.2 billion.
For investors, determining the potential profitability of the investment also depends on the performance of the company’s management. In the past 12 months, ResMed Inc.’s return on assets was 10.30%. For the broader industry, ROE averaged 3.96 over the past year.
For the three-month period that ended June 29, ResMed Inc. had $643.35 million in total debt. In the quarter under review, the net income was up than the previous quarter. The company posted a net income of $195.1 million in the quarter, while revenues of -$78.48 million were grew 8.85%. The analyst consensus anticipated ResMed Inc.’s latest quarter earnings to come in at $1.3 per share, but it turned out to be $1.35, a 3.80% surprise. For the quarter, EBITDA amounted to $287.32 million. Shareholders own equity worth $145.68 million.
From a technical analysis perspective, let’s take a brief look at ResMed Inc. (RMD) price momentum. RSI 9-day as of the close on 22 October was 65.87%, suggesting the stock is Neutral, with historical volatility in this time frame at 5.48%.
As of today, RMD’s price is $261.83 +4.70% or $12.01 from its 5-day moving average. RMD is currently trading -4.29% lower than its 20-day SMA and +31.41% higher than its 100-day SMA. However, the stock’s current price level is -2.80% below the SMA50 and +24.27% above the SMA200.
The stochastic %K and %D were 91.17% and 73.68%, respectively, and the average true range (ATR) was 5.01. With the 14-day stochastic at 96.31% and the average true range at 5.20, the RSI (14) stands at 54.42%. The stock has reached 5.80 on the 9-day MACD Oscillator while the 14-day reading was at 6.97.
CLSA upgraded ResMed Inc. (NYSE: RMD) to a an Outperform rating in its most recent analyst report. Previously, the stock was rated as an Underperform. The consensus rating for ResMed Inc. (RMD) among analysts is Hold. According to current brokerage recommendations, 1 brokerage firm advise that investors sell RMD, while 11 suggest investors hold. There are 2 analysts who rate the stock as underweight. The stock is rated overweight by 3 analysts, while 5 others rate it as a “buy”.
What is RMD’s price target for the next 12 months?
Analysts predict a range of price targets between $233.00 and $324.70, with a median target of $282.02. Taking a look at these predictions, the average price target given by analysts for ResMed Inc. (RMD) stock is $281.32.